VALEANT'S VIRAMIDINE FAILS TO MEET EFFICACY GOAL IN TREATING HEPATITIS C

Valeant Pharmaceuticals has announced that the overall response rate for its drug Viramidine in treating hepatitis C was lower than expected, although the safety profile of the drug was superior to the standard drug ribavirin.

Viramidine (taribavirin hydrochloride) is a nucleoside analog prodrug of Ribavirin, in oral form, for administration in combination with a pegylated interferon for the treatment of chronic hepatitis C.